These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23602852)

  • 21. T-cell therapy for chronic viral hepatitis.
    Bertoletti A; Tan AT; Koh S
    Cytotherapy; 2017 Nov; 19(11):1317-1324. PubMed ID: 28847469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differing prospects for the future of using gene therapy to treat infections with hepatitis B virus and hepatitis C virus.
    Ely A; Arbuthnot P
    Discov Med; 2015 Sep; 20(109):137-43. PubMed ID: 26463095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Interferon therapy of chronic viral hepatitis in Hungary: 5-year experience. A multicenter study].
    Pár A; Telegdy L; Gógl A; Müller E
    Orv Hetil; 1999 May; 140(22):1227-33. PubMed ID: 10377733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defining optimal therapeutic outcomes in chronic hepatitis.
    Lisker-Melman M; Sayuk GS
    Arch Med Res; 2007 Aug; 38(6):652-60. PubMed ID: 17613357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiological and clinical evaluation of hepatitis B, hepatitis C, and delta hepatitis viruses in Tajikistan.
    Khan A; Kurbanov F; Tanaka Y; Elkady A; Sugiyama M; Dustov A; Mizokami M
    J Med Virol; 2008 Feb; 80(2):268-76. PubMed ID: 18098133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference.
    Jardi R; Rodriguez F; Buti M; Costa X; Cotrina M; Galimany R; Esteban R; Guardia J
    Hepatology; 2001 Aug; 34(2):404-10. PubMed ID: 11481626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modelling of viral dynamics in hepatitis B and hepatitis C clinical trials.
    Sypsa V; Hatzakis A
    Stat Med; 2008 Dec; 27(30):6505-21. PubMed ID: 18951370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus.
    Tamori A; Nishiguchi S; Shiomi S; Hayashi T; Kobayashi S; Habu D; Takeda T; Seki S; Hirohashi K; Tanaka H; Kubo S
    Am J Gastroenterol; 2005 Aug; 100(8):1748-53. PubMed ID: 16086711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis B virus and hepatitis C virus dual infection among patients with chronic liver disease.
    Saravanan S; Velu V; Nandakumar S; Madhavan V; Shanmugasundaram U; Murugavel KG; Balakrishnan P; Kumarasamy N; Solomon S; Thyagarajan SP
    J Microbiol Immunol Infect; 2009 Apr; 42(2):122-8. PubMed ID: 19597643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The liver-cytokine-brain circuit in interferon-based treatment of patients with chronic viral hepatitis.
    Stasi C; Zignego AL; Laffi G; Rosselli M
    J Viral Hepat; 2011 Aug; 18(8):525-32. PubMed ID: 21762284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From HCV To HBV Cure.
    Schinazi RF; Asselah T
    Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):73-80. PubMed ID: 28052627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Core promoter mutations 3 years after anti-hepatitis B e seroconversion in patients with chronic hepatitis B or hepatitis B and C infection and cancer remission.
    Zampino R; Marrone A; Karayiannis P; Cirillo G; del Giudice EM; Rania G; Utili R; Ruggiero G
    Am J Gastroenterol; 2002 Sep; 97(9):2426-31. PubMed ID: 12358268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential risk factors for the reactivation of the replication of hepatitis B and C viruses after transcatheter arterial chemoembolization of hepatocellular carcinoma.
    Lin CI; Lin ZY; Hsieh MY; Huang CF; Chen SH; Chuang WL
    Kaohsiung J Med Sci; 2011 Dec; 27(12):554-9. PubMed ID: 22208538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical impact of hepatitis B and C virus envelope glycoproteins.
    Jeulin H; Velay A; Murray J; Schvoerer E
    World J Gastroenterol; 2013 Feb; 19(5):654-64. PubMed ID: 23429668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.
    Rockstroh JK; Bhagani S; Benhamou Y; Bruno R; Mauss S; Peters L; Puoti M; Soriano V; Tural C;
    HIV Med; 2008 Feb; 9(2):82-8. PubMed ID: 18257771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Profound suppression of chronic hepatitis C following superinfection with hepatitis B virus.
    Coffin CS; Mulrooney-Cousins PM; Lee SS; Michalak TI; Swain MG
    Liver Int; 2007 Jun; 27(5):722-6. PubMed ID: 17498260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients.
    Coffin CS; Osiowy C; Myers RP; Gill MJ
    J Clin Virol; 2013 Jun; 57(2):103-8. PubMed ID: 23465393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.
    Chien RN
    J Gastroenterol Hepatol; 2010 May; 25(5):852-7. PubMed ID: 20546437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The epidemiology and natural history of HIV/HBV and HIV/HCV co-infections.
    Mathews G; Bhagani S
    J HIV Ther; 2003 Nov; 8(4):77-84. PubMed ID: 14671504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.